A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

Study Status

Open to Enrollment

Study Description

This study is for HIV-negative and HIV-positive men and women who are suspected of having pulmonary TB who are undergoing sputum evaluation for pulmonary TB.

This study is evaluating the Xpert MTB/RIF assay, which is a new faster test to diagnose TB and to test for rifampin resistance. The study will see if Xpert MTB/RIF is as accurate as or even more accurate than the current tests. Participants will not receive any TB treatment through this study.

For the convenience of our study participants, we have 2 locations:

Chelsea: 119 West 24th Street

Upper East Side/East 68th Street: Baker 24 at NewYork-Presbyterian/Weill Cornell Medical Center

Sponsor

ACTG

Key Eligibility

  • Men and women age 18 and older
  • HIV-positive or HIV-negative
  • Suspected pulmonary TB
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Tim Wilkin, MD

Contact

Protocol ID

A5295


Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page